Opinion|Videos|February 29, 2024
COSMOS-CRC-03: ctDNA and Recurrence in Colorectal Cancer
The expert panel provides a comprehensive overview of the COSMOS-CRC-03 study and touch on the importance of also looking at real-world data.
Advertisement
Episodes in this series
Advertisement
Related to this article
The oral KRAS G12D inhibitor VS-7375 produced responses in pancreatic, colorectal, and lung cancers in the phase 1/2 TARGET-D 101 trial.
The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Reading a Changed Eye Examination and Impact on Therapy
2
Operationalizing the First Dose and Building the Oncology and Eye Care Partnership
3
FDA Expands Approval for Nogapendekin Alfa in BCG-Unresponsive NMIBC
4
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
5